Tesamorelin, a human growth hormone releasing factor analogue.

BACKGROUND

The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human growth hormone (rhGH) in therapy for growth hormone (GH)-deficient disorders has led to the development of human growth hormone releasing factor (GFR) analogues, which may be better tolerated. Tesamorelin, a synthetic GFR, has been developed as a potential treatment for a variety of conditions that may be associated with a relative deficiency of GH including HIV-related lipodystrophy.

OBJECTIVE

This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications.

METHODS

Relevant articles and abstracts were obtained from searches of the medical and chemical literature databases and the references from published articles.

RESULTS/

CONCLUSION

A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.